Omeros

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omeros reports record earnings, navigates FDA challenges for growth

Omeros showcased strong financial performance, a robust pipeline, and strategic partnerships in Q4 2022.
While challenges like FDA concerns and tight timelines exist, the company is well-positioned to capitalize on growth opportunities.
With a focus on advancing key programs and maintaining financial stability, Omeros aims to deliver value to shareholders and patients.

Omeros reports Q1 loss, progresses in key programs amid challenges

Omeros' Q1 2023 performance reflected a shift from net income to a significant loss, driven by increased expenses and reduced income, while maintaining a strong cash position and positive sales figures for OMIDRIA.
The company showcased strengths in diversified revenue streams, progress in key clinical programs, and inclusion in the Russell 3000 Index, signaling growth potential and market recognition.
Challenges in regulatory processes, market competition, and resource allocation were evident, requiring strategic navigation and operational efficiency to overcome hurdles and drive future success.
Amidst challenges, Omeros identified opportunities in expanding royalties, advancing clinical programs, exploring new indications, and leveraging immuno-oncology advancements to drive future growth and innovation.

Omeros reports Q2 loss, eyes FDA decisions and revenue growth

Omeros faces challenges with debt maturity and regulatory approvals but benefits from strong revenue streams
The company's pipeline shows promise in addressing various diseases, with a focus on high unmet medical needs
Opportunities lie in expanding revenue through OMIDRIA and advancing key drug candidates towards approval

Omeros reports Q3 losses, highlights pipeline strength and regulatory progress

Omeros demonstrated a mixed financial performance in Q3 2023 but showcased strength in its pipeline and strategic alignment with regulatory authorities.
Challenges persist in financial metrics and regulatory timelines, necessitating a balance between innovation and operational efficiency.
The company's opportunities in immuno-oncology and stable revenue streams position Omeros for future growth and impact in the biopharmaceutical landscape.

Omeros extends cash runway, advances key pipeline candidates for growth

Omeros demonstrated improved financial performance, securing additional funding and advancing key pipeline candidates, positioning the company for future growth.
While facing challenges in regulatory processes and anticipated losses, Omeros' strategic priorities and innovative pipeline offer opportunities for long-term success.
Management's focus on financial stability, operational efficiency, and product differentiation underscores Omeros' commitment to delivering value to shareholders and patients.

Omeros reports increased net loss but optimistic about pipeline progress

Omeros faced a significant increase in net loss in Q1 2024 but maintains a strong financial position with $230.3 million in cash and investments.
The company's development programs, especially OMS906, show promise with positive trial results and potential milestone payments tied to OMIDRIA sales.
While challenges like regulatory approvals and competition exist, Omeros is optimistic about its pipeline and aims for Phase III trials and regulatory successes.
Overall, Omeros is strategically positioned to leverage opportunities for growth and diversification in the biopharmaceutical market.

Omeros reports improved Q3 performance with promising drug developments

Omeros' Q3 2024 performance showed improvements in net loss and strategic financial decisions.
The company's strengths lie in potential revenue streams from OMIDRIA sales and positive trial data.
Challenges include regulatory hurdles and managing costs amidst multiple development programs.
Opportunities exist in sales growth, milestone payments, and advancing key drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The narsoplimab program hasn't proceeded as swimmingly as investors thought.

Here's Why Omeros Stock Is Tanking Today

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA's ongoing review of the company's Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. FDA stated tha

Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA

The biotech stock was part of a larger Wall Street sell-off.

Why Omeros Stock Is Plummeting This Week

Omeros' rescheduled PDUFA is upcoming on 10/17/2021. Its chances for gain in case of favorable FDA decision present a compelling risk-reward scenario for shareholders.

Omeros: The Prize Is Nigh (Again)

Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call Transcript

Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates

Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the estimate of ($0.57).

Omeros: Q2 Earnings Insights

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30,

Omeros Corporation Reports Second Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone, p

Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline

Omeros has had its PDUFA delayed by three months. The reason is that the FDA needs additional time to review data it had asked for.

Omeros: PDUFA Delay Presents An Opportunity

Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Data were shared at the European Hematology Association (EHA).

Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA). The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adu

Omeros' Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association

Omeros (OMER) announces initial results from a phase I study of OMS906.

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced publication of the article “Selective inhibition of phosphodiesterase 7 enzymes reduces motivation fo

Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT. The presentation will be webcast. The live and archived webcasts can be accessed at https://investor.omeros.com/upcoming-events. The archived webcast

Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906. The ongoing trial

Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906

Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.

Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients

Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. The patients were part of the "second surge" of COVID-19 in Italy.

Omeros's Narsoplimab Shows Encouraging Action In Critically Ill COVID-19 Patients

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplim

Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

Omeros Corporation (NASDAQ: OMER) has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The new target action date is October 17, compared to the earlier date of July 17.

Omeros's Narsoplimab US Application Review Pushed By 3 Months, Shares Drop

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today reported that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics

Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros' pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress. The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult Patients with Hi

Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress

Omeros Corp (OMER) CEO Gregory Demopulos on Q1 2021 Results - Earnings Call Transcript

News for Omeros Stock (OMER)